An overview of the c-MET signaling pathway

Therapeutic Advances in Medical Oncology
3, S7-S19
DOI: 10.1177/1758834011422556

Citation Report

#	Article	IF	Citations
1	Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. Korean Journal of Pathology, 2012, 46, 515.	1.2	25
2	Therapeutic potential of c-MET inhibitors: background and clinical data. Clinical Investigation, 2012, 2, 301-315.	0.0	1
3	Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice. Hepatology, 2012, 56, 1913-1923.	3.6	27
4	Oncogenic driver mutations in lung cancer. Translational Respiratory Medicine, 2013, 1, 6.	3.8	49
5	Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2013, 22, 499-515.	1.9	48
6	<scp>MET</scp> Gain in Diffuse Astrocytomas is Associated with Poorer Outcome. Brain Pathology, 2013, 23, 13-18.	2.1	37
7	Increased TGF-Î± as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFRâ€"MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	3.2	130
8	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design, 2013, 19, 940-950.	0.9	61
9	Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Metâ€"driven Pancreatic Carcinoma. Cancer Research, 2013, 73, 6745-6756.	0.4	79
10	Esophageal carcinoma. Current Opinion in Oncology, 2013, 25, 417-424.	1.1	10
11	KRAS Mutations as Prognostic and Predictive Markers in Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 530-542.	0.5	104
12	Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. International Journal of Oncology, 2013, 42, 848-862.	1.4	57
13	Expression of ST3GAL4 Leads to SLex Expression and Induces c-Met Activation and an Invasive Phenotype in Gastric Carcinoma Cells. PLoS ONE, 2013, 8, e66737.	1.1	96
14	c-MET Regulates Myoblast Motility and Myocyte Fusion during Adult Skeletal Muscle Regeneration. PLoS ONE, 2013, 8, e81757.	1.1	57
15	Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. OncoTargets and Therapy, 2014, 7, 1933.	1.0	53
16	A novel role for ezrin in breast cancer angio/lymphangiogenesis. Breast Cancer Research, 2014, 16, 438.	2.2	36
17	Pleiotropic Activities of HGF/c-Met System in Testicular Physiology: Paracrine and Endocrine Implications. Frontiers in Endocrinology, 2014, 5, 38.	1.5	14
18	Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274. Biomedical Reports, 2014, 2, 799-803.	0.9	5

#	Article	IF	Citations
19	Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS Medicinal Chemistry Letters, 2014, 5, 1219-1224.	1.3	41
20	MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. Clinical Cancer Research, 2014, 20, 3411-3421.	3.2	142
21	Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). Histopathology, 2014, 65, 879-896.	1.6	15
22	RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocrine-Related Cancer, 2014, 21, 311-326.	1.6	74
23	The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance. , 2014, 142, 316-338.		174
24	Huge clusters of embryonic stem cells in human embryos: A morphologic study. Microscopy Research and Technique, 2014, 77, 825-831.	1.2	5
25	c-MET Inhibitors in the Treatment of Lung Cancer. Current Treatment Options in Oncology, 2014, 15, 670-682.	1.3	53
26	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Research, 2014, 24, 1765-1773.	2.4	316
27	Cytoplasmic hepatocyte growth factor immunoreactivity predicting lymph node metastasis in esophageal squamous cell carcinoma. Esophagus, 2014, 11, 223-230.	1.0	1
28	HGF Induces Epithelial-to-Mesenchymal Transition by Modulating the Mammalian Hippo/MST2 and ISG15 Pathways. Journal of Proteome Research, 2014, 13, 2874-2886.	1.8	82
29	Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. , 2014, 143, 337-349.		16
30	The apoptotic perspective of autism. International Journal of Developmental Neuroscience, 2014, 36, 13-18.	0.7	80
31	SU11274 suppresses proliferation and motility of pancreatic cancer cells. Oncology Letters, 2015, 10, 1468-1472.	0.8	2
32	The cytohesin guanosine exchange factors (GEFs) are required to promote HGF-mediated renal recovery after acute kidney injury (AKI) in mice. Physiological Reports, 2015, 3, e12442.	0.7	13
33	Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood, 2015, 126, 2821-2831.	0.6	43
34	Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway. Molecular Medicine Reports, 2015, 12, 3265-3272.	1.1	21
35	Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. Journal of Experimental and Clinical Cancer Research, 2015, 34, 112.	3.5	41
36	From Uniplex to Multiplex Molecular Profiling in Advanced Nonâ€"Small Cell Lung Carcinoma. Cancer Journal (Sudbury, Mass), 2015, 21, 413-424.	1.0	3

#	Article	IF	Citations
37	Molecular characterization of oral squamous cell carcinoma using targeted nextâ€generation sequencing. Oral Diseases, 2015, 21, 872-878.	1.5	25
38	Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience, 2015, 9, 3.	1.8	13
39	Topical Application of Oleuropein Induces Anagen Hair Growth in Telogen Mouse Skin. PLoS ONE, 2015, 10, e0129578.	1.1	32
40	Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Management and Research, 2015, 7, 253.	0.9	66
41	Expression of HGF and c-Met Proteins in Human Keratoconus Corneas. Journal of Ophthalmology, 2015, 2015, 1-8.	0.6	18
42	Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. BioMed Research International, 2015, 2015, 1-22.	0.9	23
43	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
44	Gene of the month: MET. Journal of Clinical Pathology, 2015, 68, 405-409.	1.0	43
45	Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Molecular Cancer, 2015, 14, 103.	7.9	110
46	The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. Laboratory Investigation, 2015, 95, 951-961.	1.7	12
47	Therapeutic potential of hepatocyte growth factor against cerebral ischemia (Review). Experimental and Therapeutic Medicine, 2015, 9, 283-288.	0.8	19
48	IKKÎ² acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. Journal of Experimental Medicine, 2015, 212, 2253-2266.	4.2	116
49	Novel Role for Î³-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1). Journal of Biological Chemistry, 2015, 290, 15610-15620.	1.6	22
50	MET. , 2015, , 1-14.		0
51	PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nature Communications, 2015, 6, 6064.	5.8	64
52	Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 2513-2529.	2.9	42
53	A mutation ofMET, encoding hepatocyte growth factor receptor, is associated with humanDFNB97hearing loss. Journal of Medical Genetics, 2015, 52, 548-552.	1.5	58
54	Enigmas of IDH mutations in hematology/oncology. Experimental Hematology, 2015, 43, 685-697.	0.2	22

#	Article	IF	Citations
55	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	3.4	71
56	Dose-dependent modulation of myogenesis by HGF: implications for c-Met expression and downstream signalling pathways. Growth Factors, 2015, 33, 229-241.	0.5	26
57	Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Cancer Gene Therapy, 2015, 22, 262-270.	2.2	16
58	Radiation Therapy for Glioma Stem Cells. Advances in Experimental Medicine and Biology, 2015, 853, 85-110.	0.8	14
59	High levels of c-Met is associated with poor prognosis in glioblastoma. Journal of Neuro-Oncology, 2015, 122, 517-527.	1.4	62
60	HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer, 2015, 88, 34-41.	0.9	17
61	Src-dependent Tyrosine Phosphorylation of Non-muscle Myosin Heavy Chain-IIA Restricts Listeria monocytogenes Cellular Infection. Journal of Biological Chemistry, 2015, 290, 8383-8395.	1.6	22
62	c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer, 2015, 15, 451.	1.1	36
63	Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future. Gynecologic Oncology Research and Practice, 2015, 2, 8.	3.6	9
64	Kidney cancer and 2014: is innovation really over?. Future Oncology, 2015, 11, 1437-1449.	1.1	1
65	Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold. Bioorganic and Medicinal Chemistry, 2015, 23, 564-578.	1.4	15
66	Coordinated Messenger RNA/MicroRNA Changes in Fibroblasts of Patients with Major Depression. Biological Psychiatry, 2015, 77, 256-265.	0.7	57
67	Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer: Targets and Therapy, 2016, Volume 8, 183-197.	1.0	30
68	A Review on Bladder Wound Healing after Mechanical Injury. Journal of Tissue Science & Engineering, 2016, 7, .	0.2	5
69	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 172-182.	1.3	80
70	Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics, 2016, 6, 2028-2038.	4.6	15
71	A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion. PLoS ONE, 2016, 11, e0146931.	1.1	29
72	The Genetic Intersection of Neurodevelopmental Disorders and Shared Medical Comorbidities â€“ Relations that Translate from Bench to Bedside. Frontiers in Psychiatry, 2016, 7, 142.	1.3	29

#	Article	IF	Citations
73	Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Research, 2016, 26, 354-360.	0.6	13
74	Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Molecular Carcinogenesis, 2016, 55, 2037-2050.	1.3	25
75	Similar requirement for clathrin in EGF- and HGF- stimulated Akt phosphorylation. Communicative and Integrative Biology, 2016, 9, e1175696.	0.6	16
76	Hepatocyte growth factor/câ€met promotes proliferation, suppresses apoptosis, and improves matrix metabolism in rabbit nucleus pulposus cells in vitro. Journal of Orthopaedic Research, 2016, 34, 709-716.	1.2	27
77	Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Research, 2016, 76, 4970-4980.	0.4	102
78	Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment. Scientific Reports, 2016, 6, 33026.	1.6	45
79	Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. Scientific Reports, 2016, 6, 20065.	1.6	54
80	Polarized monolayer cultures of human intestinal epithelial cell lines exposed to intractable proteins - InÂvitro hazard identification studies. Food and Chemical Toxicology, 2016, 98, 262-268.	1.8	9
81	Receptor Tyrosine Kinase MET Interactome and Neurodevelopmental Disorder Partners at the Developing Synapse. Biological Psychiatry, 2016, 80, 933-942.	0.7	16
82	Molecular Signaling in Oral Cancer Invasion and Metastasis. , 2016, , 71-99.		1
83	Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clinical and Translational Gastroenterology, 2016, 7, e179.	1.3	45
84	(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies. Bioorganic and Medicinal Chemistry, 2016, 24, 5748-5761.	1.4	13
85	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	3.4	46
86	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	2.1	73
87	Elevated hepatocyte growth factor expression as an autocrine câ€Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Science, 2016, 107, 407-416.	1.7	103
88	The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2016, 1, 369-377.	0.4	2
89	Role of Sphingosine Kinase 1 and S1P Transporter Spns2 in HGF-mediated Lamellipodia Formation in Lung Endothelium. Journal of Biological Chemistry, 2016, 291, 27187-27203.	1.6	32
90	Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. BMC Cancer, 2016, 16, 599.	1.1	23

#	Article	IF	Citations
91	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 1450-1460.	1.9	101
92	RNA-Sequencing for profiling goat milk transcriptome in colostrum and mature milk. BMC Veterinary Research, 2016, 12, 264.	0.7	71
93	Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2201-2214.	1.7	36
94	Molecular Radio-Oncology. Recent Results in Cancer Research, 2016, , .	1.8	1
95	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. Recent Results in Cancer Research, 2016, 198, 107-122.	1.8	12
96	Toward precision medicine of breast cancer. Theoretical Biology and Medical Modelling, 2016, 13, 7.	2.1	48
97	Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting Câ€Met. Phytotherapy Research, 2016, 30, 557-566.	2.8	53
98	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 707-714.	1.2	8
99	Ggnbp2 Is Essential for Pregnancy Success via Regulation of Mouse Trophoblast Stem Cell Proliferation and Differentiation1. Biology of Reproduction, 2016, 94, 41.	1.2	13
100	MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Nonâ€"Small Cell Lung Carcinoma with Poor Prognosis. Clinical Cancer Research, 2016, 22, 3048-3056.	3.2	352
101	Transcriptional silencing of long noncoding RNA GNG12-AS1 uncouples its transcriptional and product-related functions. Nature Communications, 2016, 7, 10406.	5.8	77
102	MiRNA 34a: a therapeutic target for castration-resistant prostate cancer. Expert Opinion on Therapeutic Targets, 2016, 20, 1075-1085.	1.5	11
103	CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1â€"Dependent IGF-1 Signaling. Cancer Research, 2016, 76, 2687-2697.	0.4	29
104	Degradable Acetalated Dextran Microparticles for Tunable Release of an Engineered Hepatocyte Growth Factor Fragment. ACS Biomaterials Science and Engineering, 2016, 2, 197-204.	2.6	26
105	Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease. Cancer Genetics, 2016, 209, 11-20.	0.2	10
106	Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. Journal of Cancer Research and Clinical Oncology, 2016, 142, 125-133.	1.2	12
107	Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction. Reproductive Sciences, 2017, 24, 494-501.	1.1	26
108	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	1.6	49

#	Article	IF	Citations
109	Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor. Annals of Diagnostic Pathology, 2017, 28, 12-18.	0.6	13
110	c-Met expression and activity in urogenital cancers â€“ novel aspects of signal transduction and medical implications. Cell Communication and Signaling, 2017, 15, 10.	2.7	25
111	Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway. Oncology Reports, 2017, 37, 1203-1211.	1.2	54
112	The mitogen-activated protein kinase pathway in melanoma part I â€“ Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer, 2017, 73, 85-92.	1.3	96
113	An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 583-597.	2.5	164
114	Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Research, 2017, 7, 41.	1.1	12
115	AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncology Reports, 2017, 37, 2201-2208.	1.2	12
116	Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors. Journal of Molecular Graphics and Modelling, 2017, 75, 241-249.	1.3	11
117	MET. , 2017, , 773-786.		0
118	Specificity protein 1: Its role in colorectal cancer progression and metastasis. Critical Reviews in Oncology/Hematology, 2017, 113, 1-7.	2.0	48
119	Role of microRNAs in endocrine cancer metastasis. Molecular and Cellular Endocrinology, 2017, 456, 62-75.	1.6	62
120	CERNA SEARCH METHOD IDENTIFIED A MET-ACTIVATED SUBGROUP AMONG EGFR DNA AMPLIFIED LUNG ADENOCARCINOMA PATIENTS. , 2017, 22, 438-448.		1
121	Autologous NeoHep Derived from Chronic Hepatitis B Virus Patientsâ€™ Blood Monocytes by Upregulation of c-MET Signaling. Stem Cells Translational Medicine, 2017, 6, 174-186.	1.6	2
122	Interleukin 35 and Hepatocyte Growth Factor; as a novel combined immune gene therapy for Multiple Sclerosis disease. Medical Hypotheses, 2017, 109, 102-105.	0.8	14
123	Hepatic progenitor cell activation in liver repair. Liver Research, 2017, 1, 81-87.	0.5	30
124	High glucose induces HGF-independent activation of Met receptor in human renal tubular epithelium. Journal of Receptor and Signal Transduction Research, 2017, 37, 535-542.	1.3	17
125	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology and Therapy, 2017, 18, 694-704.	1.5	13
126	Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas. Biochimie, 2017, 142, 135-143.	1.3	10

#	Article	IF	Citations
127	Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLCâ€"MS/MS for application to a pharmacokinetic study in rats. Journal of Separation Science, 2017, 40, 3782-3791.	1.3	6
128	Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics, 2017, 16, 2387-2398.	1.9	30
129	Negative control of the HGF/c-MET pathway by TGF-Î²: a new look at the regulation of stemness in glioblastoma. Cell Death and Disease, 2017, 8, 3210.	2.7	30
130	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer, 2017, 87, 147-163.	1.3	108
131	Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. Journal of Hematology and Oncology, 2017, 10, 19.	6.9	40
132	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. Journal of Thoracic Oncology, 2017, 12, 15-26.	0.5	299
133	Responses to Crizotinib Can Occur in High-Level MET -Amplified Nonâ€"Small Cell Lung Cancer Independent of MET Exon 14 Alterations. Journal of Thoracic Oncology, 2017, 12, 141-144.	0.5	61
134	The Pleiotropic MET Receptor Network: Circuit Development and the Neural-Medical Interface of Autism. Biological Psychiatry, 2017, 81, 424-433.	0.7	32
135	Naturally occurring InlB variants that support intragastric Listeria monocytogenes infection in mice. FEMS Microbiology Letters, 2017, 364, fnx011.	0.7	13
136	A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 1786.	1.8	119
137	Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. International Journal of Molecular Sciences, 2017, 18, 1968.	1.8	12
138	Cabozantinib. , 2017, , 457-480.		2
139	Tetraspanins Function as Regulators of Cellular Signaling. Frontiers in Cell and Developmental Biology, 2017, 5, 34.	1.8	196
140	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers, 2017, 9, 87.	1.7	53
141	Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers, 2017, 9, 169.	1.7	51
142	Potential Sabotage of Host Cell Physiology by Apicomplexan Parasites for Their Survival Benefits. Frontiers in Immunology, 2017, 8, 1261.	2.2	34
143	Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers. Frontiers in Immunology, 2017, 8, 1746.	2.2	45
144	Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators of Inflammation, 2017, 2017, 1-21.	1.4	131

#	Article	IF	Citations
145	HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway. Skeletal Muscle, 2017, 7, 20.	1.9	40
146	Retinal and choroidal angiogenesis: a review of new targets. International Journal of Retina and Vitreous, 2017, 3, 31.	0.9	112
147	Systemic therapy for advanced hepatocellular carcinoma: an update. Journal of Gastrointestinal Oncology, 2017, 8, 243-255.	0.6	55
148	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2077-E2084.	3.3	32
149	Regulation of Signal Transduction in Human Cell Research. Current Human Cell Research and Applications, 2018, , .	0.1	0
150	Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine. Anti-Cancer Drugs, 2018, 29, 295-306.	0.7	3
151	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist, 2018, 23, 540-555.	1.9	57
152	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nature Genetics, 2018, 50, 708-717.	9.4	212
153	Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor Î²/IL-1/c-MET signals. Cancer Letters, 2018, 430, 215-223.	3.2	29
154	MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met. Experimental and Therapeutic Medicine, 2018, 15, 2301-2306.	0.8	15
155	Apoptotic impact on Brugia malayi by sulphonamido-quinoxaline: search for a novel therapeutic rationale. Parasitology Research, 2018, 117, 1559-1572.	0.6	6
156	Receptorâ€Targeted Drug Delivery and the (Many) Problems We Know of: The Case of CD44 and Hyaluronic Acid. Advanced Biology, 2018, 2, 1800049.	3.0	14
157	Cigarette smoke enhances oncogene addiction to câ€•MET and desensitizes EGFR â€expressing nonâ€small cell lung cancer to EGFR TKI s. Molecular Oncology, 2018, 12, 705-723.	2.1	21
158	ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma. Experimental Cell Research, 2018, 363, 271-282.	1.2	9
159	Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 698-709.	1.9	9
160	Cellular Biomechanics in Skeletal Muscle Regeneration. Current Topics in Developmental Biology, 2018, 126, 125-176.	1.0	31
161	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 â€˜CREATEâ€™. Annals of Oncology, 2018, 29, 758-765.	0.6	67
162	Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Molecular Cancer, 2018, 17, 26.	7.9	47

#	Article	IF	Citations
163	Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Scientific Reports, 2018, 8, 4177.	1.6	34
164	ISG15 promotes esophageal squamous cell carcinoma tumorigenesis via c-MET/Fyn/Î²-catenin signaling pathway. Experimental Cell Research, 2018, 367, 47-55.	1.2	34
165	MET Expression in Advanced Nonâ€"Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clinical Lung Cancer, 2018, 19, e441-e463.	1.1	61
166	Acute kidney injury: emerging pharmacotherapies in current clinical trials. Pediatric Nephrology, 2018, 33, 779-787.	0.9	34
167	Clinical and prognostic value of the Câ€Met/HGF signaling pathway in cervical cancer. Journal of Cellular Physiology, 2018, 233, 4490-4496.	2.0	38
168	Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives. Journal of Pharmacy and Pharmacology, 2018, 70, 151-158.	1.2	17
169	Recent advances in the discovery of small molecule c-Met Kinase inhibitors. European Journal of Medicinal Chemistry, 2018, 143, 1103-1138.	2.6	116
170	Developmentally regulated signaling pathways in glioma invasion. Cellular and Molecular Life Sciences, 2018, 75, 385-402.	2.4	63
171	Involvement of the Urokinase Receptor and Its Endogenous Ligands in the Development of the Brain and the Formation of Cognitive Functions. Neuroscience and Behavioral Physiology, 2018, 48, 16-27.	0.2	3
172	Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model. Journal of Theoretical Biology, 2018, 439, 86-99.	0.8	20
173	The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chemical Biology, 2018, 25, 67-77.e3.	2.5	422
174	The untold stories of the speech gene, the FOXP2 cancer gene. Genes and Cancer, 2018, 9, 11-38.	0.6	23
175	Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action. Oncotarget, 2018, 9, 26466-26490.	0.8	57
176	c-Met Signaling Protects from Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	1.9	9
177	Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. Biochemical and Biophysical Research Communications, 2018, 507, 311-318.	1.0	4
178	Epithelial invasion by<scp>SalmonellaTyphi</scp>using<scp>STIV</scp>â€"<scp>Met</scp>interaction. Cellular Microbiology, 2019, 21, e12982.	1.1	8
179	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	0.8	19
180	Predicting Tumor Growth and Ligand Dependence from mRNA by Combining Machine Learning with Mechanistic Modeling. Methods in Pharmacology and Toxicology, 2018, , 1.	0.1	0

#	Article	IF	Citations
181	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
182	Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 3300.	1.8	44
183	An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer. Cellular and Molecular Biology Letters, 2018, 23, 51.	2.7	14
184	Biomarkers of Acute Kidney Injury. , 2018, , 147-163.		4
185	Prevalence of Hepatocyte Growth Factor and Autoantibodies to Î±-HGF as a New Etiology for Bilateral Diffuse Uveal Melanocytic Proliferation Masquerading as Neovascular Age-Related Macular Degeneration. Journal of Clinical & Experimental Ophthalmology, 2018, 09, .	0.1	18
186	Novel insights into the host immune response of chicken Harderian gland tissue during Newcastle disease virus infection and heat treatment. BMC Veterinary Research, 2018, 14, 280.	0.7	33
187	Hepatocyte Growth Factor (HGF) Promotes Peripheral Nerve Regeneration by Activating Repair Schwann Cells. Scientific Reports, 2018, 8, 8316.	1.6	70
189	Cross-talk between human airway epithelial cells and 3T3-J2 feeder cells involves partial activation of human MET by murine HGF. PLoS ONE, 2018, 13, e0197129.	1.1	11
190	Induction ofÂnerve growth factor byÂphorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway. Heliyon, 2018, 4, e00617.	1.4	3
191	miRâ€26a modulates HGF and STAT3 effects on the kidney repair process in a glycerolâ€induced AKI model in rats. Journal of Cellular Biochemistry, 2018, 119, 7757-7766.	1.2	6
192	Scatter Factor/HGF and c-Met in Glioblastoma. , 2018, , 341-346.		0
193	Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of Immunology Research, 2018, 2018, 1-16.	0.9	89
194	Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. Medical Oncology, 2018, 35, 122.	1.2	22
195	Combined Systemic Disruption of MET and Epidermal Growth Factor Receptor Signaling Causes Liver Failure in Normal Mice. American Journal of Pathology, 2018, 188, 2223-2235.	1.9	20
196	Developments in Point-of-Care Diagnostic Technology for Cancer Detection. Diagnostics, 2018, 8, 39.	1.3	72
197	Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling. International Journal of Molecular Sciences, 2018, 19, 580.	1.8	81
198	Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. Neoplasia, 2018, 20, 838-847.	2.3	25
199	The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Molecular Cancer, 2018, 17, 27.	7.9	36

#	Article	IF	Citations
200	Chimeric HDAC inhibitors: Comprehensive review on the HDACâ€based strategies developed to combat cancer. Medicinal Research Reviews, 2018, 38, 2058-2109.	5.0	107
201	Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. Experimental and Therapeutic Medicine, 2018, 15, 4229-4242.	0.8	2
202	c-Fos is necessary for HGF-mediated gene regulation and cell migration in Schwann cells. Biochemical and Biophysical Research Communications, 2018, 503, 2855-2860.	1.0	12
203	Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. PLoS Computational Biology, 2018, 14, e1006192.	1.5	26
204	miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Therapy, 2019, 26, 1-10.	2.2	20
205	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Investigational New Drugs, 2019, 37, 271-281.	1.2	7
206	3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2165-2178.	2.0	11
207	HGF promotes HTR-8/SVneo cell migration through activation of MAPK/PKA signaling leading to up-regulation of WNT ligands and integrins that target Î²-catenin. Molecular and Cellular Biochemistry, 2019, 453, 11-32.	1.4	13
208	MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population. PLoS ONE, 2019, 14, e0220670.	1.1	9
209	Bispecific Aptamer Induced Artificial Protein-Pairing: A Strategy for Selective Inhibition of Receptor Function. Journal of the American Chemical Society, 2019, 141, 12673-12681.	6.6	102
210	Impaired ligandâ€dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer. Cancer Science, 2019, 110, 3340-3349.	1.7	12
211	Curcumin as tyrosine kinase inhibitor in cancer treatment. European Journal of Medicinal Chemistry, 2019, 181, 111512.	2.6	66
212	Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. MedChemComm, 2019, 10, 1646-1655.	3.5	8
213	Mesenchymalâ€"epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 755-761.	0.6	2
214	Signal Transduction in Radiation Oncology. , 2019, , 1-17.		0
215	STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers. BMC Cancer, 2019, 19, 959.	1.1	14
216	Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death and Disease, 2019, 10, 777.	2.7	26
217	RhoA-Dependent HGF and c-Met Mediate Gas6-Induced Inhibition of Epithelialâ€"Mesenchymal Transition, Migration, and Invasion of Lung Alveolar Epithelial Cells. Biomolecules, 2019, 9, 565.	1.8	4

#	Article	IF	Citations
218	A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Kidney Cancer, 2019, 3, 151-161.	0.2	45
219	Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 362.	3.5	20
220	Verticillin A suppresses HGF-induced migration and invasion via repression of the c-Met/FAK/Src pathway in human gastric and cervical cancer cells . OncoTargets and Therapy, 2019, Volume 12, 5823-5833.	1.0	13
221	A Method for Obtaining the Real Off-State Breakdown Voltage of AlGaN/GaN MIS-HEMTs in On-Wafer Tests by Optimizing Protective Layer. IEEE Journal of the Electron Devices Society, 2019, 7, 902-907.	1.2	5
222	HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 533-566.	2.7	114
223	Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond. International Journal of Molecular Sciences, 2019, 20, 4507.	1.8	64
224	Targeting of host cell receptor tyrosine kinases by intracellular pathogens. Science Signaling, 2019, 12, .	1.6	31
225	Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. Bioconjugate Chemistry, 2019, 30, 2703-2713.	1.8	12
226	Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 2019, 8, 1102.	1.8	150
227	Generation of the heterogeneity of extracellular vesicles by membrane organization and sorting machineries. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 681-691.	1.1	20
228	Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases. International Journal of Molecular Sciences, 2019, 20, 384.	1.8	14
229	Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer, 2019, 19, 496.	1.1	17
230	MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of Hematology and Oncology, 2019, 12, 63.	6.9	181
231	Emerging biomarkers in pulmonary metastasectomy. Journal of Visualized Surgery, 2019, 5, 44-44.	0.2	1
232	De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors. Cancer Biology and Therapy, 2019, 20, 1183-1186.	1.5	7
233	The potential therapeutic and prognostic impacts of the câ€MET/HGF signaling pathway in colorectal cancer. IUBMB Life, 2019, 71, 802-811.	1.5	43
234	MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS ONE, 2019, 14, e0216400.	1.1	54
235	Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy. Cancer Biomarkers, 2019, 25, 177-184.	0.8	7

#	Article	IF	Citations
236	p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radical Biology and Medicine, 2019, 139, 24-34.	1.3	15
237	Drugs in Development for Acute Kidney Injury. Drugs, 2019, 79, 811-821.	4.9	28
238	Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nature Communications, 2019, 10, 2045.	5.8	143
239	Stimulation with Porphyromonas gingivalis enhances malignancy and initiates anoikis resistance in immortalized oral keratinocytes. Journal of Cellular Physiology, 2019, 234, 21903-21914.	2.0	9
240	MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7533-7542.	3.3	26
241	Molecular Diagnostics in Renal Cancer. , 2019, , 199-218.		4
242	Tackling Lung Cancer Drug Resistance Using Integrated Drug-Repurposing Strategy. , 2019, , 549-575.		0
243	Comparison of Coding Transcriptomes in Fibroblasts Irradiated With Low and High LET Proton Beams and Cobalt-60 Photons. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1203-1211.	0.4	7
244	Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2. Future Medicinal Chemistry, 2019, 11, 743-769.	1.1	14
245	Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells. European Journal of Pharmacology, 2019, 853, 316-324.	1.7	10
246	Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2019, 7, 60.	1.8	302
247	Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. Stem Cell Research and Therapy, 2019, 10, 111.	2.4	288
248	Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking. Journal of Molecular Biology, 2019, 431, 2020-2039.	2.0	20
249	Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer, 2019, 125, 1789-1798.	2.0	26
250	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports, 2019, 21, 21.	1.8	82
251	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. Diagnostics, 2019, 9, 13.	1.3	10
252	Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. Advances in Biological Regulation, 2019, 72, 63-77.	1.4	19
253	Papillary Renal Cell Carcinoma (PRCC): An Update. Advances in Anatomic Pathology, 2019, 26, 124-132.	2.4	97

#	Article	IF	Citations
254	ILâ€7 overexpression enhances therapeutic potential of rat bone marrow mesenchymal stem cells for diabetic wounds. Wound Repair and Regeneration, 2019, 27, 235-248.	1.5	10
255	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 6098-6106.	3.2	14
256	PROTACs: great opportunities for academia and industry. Signal Transduction and Targeted Therapy, 2019, 4, 64.	7.1	367
257	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. Cancers, 2019, 11, 2033.	1.7	26
258	Further Evidence for the Implication of the MET Gene in Non-Syndromic Autosomal Recessive Deafness. Human Heredity, 2019, 84, 109-116.	0.4	5
259	An occult urothelial carcinoma with wide multiorgan metastases and its genetic alteration profiling. Medicine (United States), 2019, 98, e15245.	0.4	4
260	Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomarker Research, 2019, 7, 27.	2.8	22
261	Analysis of the transcription factors and their regulatory roles during a step-by-step differentiation of induced pluripotent stem cells into hepatocyte-like cells. Molecular Omics, 2019, 15, 383-398.	1.4	11
262	Signalingâ€"chemokine axis network in brain as a sanctuary site for metastasis. Journal of Cellular Physiology, 2019, 234, 3376-3382.	2.0	9
263	PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. Cancer Letters, 2019, 444, 116-126.	3.2	27
264	câ€Met inhibition is required for the celecoxibâ€attenuated stemness property of human colorectal cancer cells. Journal of Cellular Physiology, 2019, 234, 10336-10344.	2.0	11
265	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 2403-2413.	3.2	40
266	Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Modern Pathology, 2019, 32, 627-638.	2.9	22
267	Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Safety, 2019, 42, 211-233.	1.4	76
268	Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy. Journal of Molecular Modeling, 2019, 25, 13.	0.8	3
269	Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. Cancer Biomarkers, 2019, 24, 71-83.	0.8	24
270	Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 145-152.	0.5	7
271	Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines. In Vitro Cellular and Developmental Biology - Animal, 2019, 55, 7-16.	0.7	1

#	Article	IF	Citations
272	Optimization techniques for novel c-Met kinase inhibitors. Expert Opinion on Drug Discovery, 2019, 14, 59-69.	2.5	16
273	Isolation and in silico prediction of potential drug-like compounds from Anethum sowa L. root extracts targeted towards cancer therapy. Computational Biology and Chemistry, 2019, 78, 242-259.	1.1	14
274	A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Investigational New Drugs, 2019, 37, 876-889.	1.2	17
275	GD2â€directed CARâ€T cells in combination with HGFâ€targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. International Journal of Cancer, 2020, 146, 3184-3195.	2.3	37
276	Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. Head and Neck, 2020, 42, 625-635.	0.9	2
277	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. Expert Review of Respiratory Medicine, 2020, 14, 367-383.	1.0	21
278	TR1801â€ADC: a highly potent cMet antibodyâ€"drug conjugate with high activity in patientâ€derived xenograft models of solid tumors. Molecular Oncology, 2020, 14, 54-68.	2.1	39
279	Fridericia platyphylla (Cham.) L.G. Lohmann root extract exerts cytotoxic and antiproliferative effects on gastric tumor cells and downregulates BCL-XL, BIRC5, and MET genes. Human and Experimental Toxicology, 2020, 39, 338-354.	1.1	12
280	Molecular Epitope Determination of Aptamer Complexes of the Multidomain Protein Câ€Met by Proteolytic Affinityâ€Mass Spectrometry. ChemMedChem, 2020, 15, 363-369.	1.6	8
281	Clinicopathologic analysis of gastric mucosa-associated lymphoid tissue lymphoma with or without c-Met expression. Medical Molecular Morphology, 2020, 53, 149-155.	0.4	2
282	cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibodyâ€"Drug Conjugate Targeting c-Met Overexpression Tumors. ACS Omega, 2020, 5, 25798-25809.	1.6	7
283	Long noncoding RNAs (lncRNAs) in cervical carcinogenesis: New molecular targets, current prospects. Critical Reviews in Oncology/Hematology, 2020, 156, 103111.	2.0	15
284	Overview of current targeted therapy in gallbladder cancer. Signal Transduction and Targeted Therapy, 2020, 5, 230.	7.1	84
285	The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives. Critical Reviews in Food Science and Nutrition, 2022, 62, 832-859.	5.4	68
286	Inhibition of câ€MET increases the antitumour activity of PARP inhibitors in gastric cancer models. Journal of Cellular and Molecular Medicine, 2020, 24, 10420-10431.	1.6	12
287	Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Translational Lung Cancer Research, 2020, 9, 603-616.	1.3	21
288	3D in vitro cutaneous melanoma models. , 2020, , 287-303.		0
289	Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention. Nature Communications, 2020, 11, 4015.	5.8	27

#	Article	IF	Citations
290	The Iris. , 2020, , .		4
291	MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury. Cells, 2020, 9, 1767.	1.8	19
292	Tyrosine kinase inhibitors for solid tumors in the past 20Âyears (2001â€“2020). Journal of Hematology and Oncology, 2020, 13, 143.	6.9	226
293	Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met. Journal of Zhejiang University: Science B, 2020, 21, 779-795.	1.3	8
294	HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression. Frontiers in Immunology, 2020, 11, 2135.	2.2	32
295	Long Non-Coding RNAs as Strategic Molecules to Augment the Radiation Therapy in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 6787.	1.8	14
296	Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways. Molecules, 2020, 25, 4279.	1.7	34
297	Achieving High Levels of Selectivity for Kinase Inhibitors. Topics in Medicinal Chemistry, 2020, , 95-123.	0.4	0
298	Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Frontiers in Oncology, 2020, 10, 610923.	1.3	61
299	Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. Cells, 2020, 9, 1313.	1.8	174
300	Imbalance Between Oxidative Stress and Growth Factors in Human High Myopia. Frontiers in Physiology, 2020, 11, 463.	1.3	14
301	C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies. Theranostics, 2020, 10, 5357-5367.	4.6	15
302	Kinetic and thermodynamic study of c-Met interaction with single chain fragment variable (scFv) antibodies using phage based surface plasmon resonance. European Journal of Pharmaceutical Sciences, 2020, 150, 105362.	1.9	1
303	TargetingMETDysregulation in Cancer. Cancer Discovery, 2020, 10, 922-934.	7.7	94
304	Targeting the MET-Signaling Pathway in Non-Smallâ€“Cell Lung Cancer: Evidence to Date . OncoTargets and Therapy, 2020, Volume 13, 5691-5706.	1.0	11
305	Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives. Cancers, 2020, 12, 1530.	1.7	15
306	Capmatinib: First Approval. Drugs, 2020, 80, 1125-1131.	4.9	67
307	Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091756.	1.4	9

#	Article	IF	Citations
308	Targeting c-Met on gastric cancer cells through a fully human fab antibody isolated from a large naive phage antibody library. DARU, Journal of Pharmaceutical Sciences, 2020, 28, 221-235.	0.9	3
309	Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Medical Oncology, 2020, 37, 24.	1.2	68
310	The Optimal Imaging Window for Dysplastic Colorectal Polyp Detection Using c-Metâ€"Targeted Fluorescence Molecular Endoscopy. Journal of Nuclear Medicine, 2020, 61, 1435-1441.	2.8	16
311	Targeted Quantification of Peptides Using Miniature Mass Spectrometry. Journal of Proteome Research, 2020, 19, 2043-2052.	1.8	10
312	Noncoding Microdeletion in MouseHgfDisrupts Neural Crest Migration into the Stria Vascularis, Reduces the Endocochlear Potential, and Suggests the Neuropathology for Human Nonsyndromic Deafness DFNB39. Journal of Neuroscience, 2020, 40, 2976-2992.	1.7	21
313	The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy. Frontiers in Oncology, 2020, 10, 54.	1.3	18
314	Structural and Functional Insight Into the Glycosylation Impact Upon the HGF/c-Met Signaling Pathway. Frontiers in Cell and Developmental Biology, 2020, 8, 490.	1.8	8
315	A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth. Integrative Cancer Therapies, 2020, 19, 153473542091744.	0.8	13
316	Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading. Oncogenesis, 2020, 9, 11.	2.1	12
317	Renal Mass Biopsy. , 2020, , .		1
318	Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors. Bioorganic Chemistry, 2020, 97, 103667.	2.0	15
319	Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy. Frontiers in Cell and Developmental Biology, 2020, 8, 23.	1.8	10
320	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
321	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 6.	6.9	13
322	lncTUG1/miR-144-3p affect the radiosensitivity of esophageal squamous cell carcinoma by competitively regulating c-MET. Journal of Experimental and Clinical Cancer Research, 2020, 39, 7.	3.5	38
323	DNA Nanotechnology on Live Cell Membranes. Chemical Research in Chinese Universities, 2020, 36, 203-210.	1.3	5
324	The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies. Toxicology and Applied Pharmacology, 2020, 398, 115018.	1.3	16
325	Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. Current Treatment Options in Oncology, 2020, 21, 33.	1.3	31

#	Article	IF	Citations
326	Hepatocyte Growth Factor in Blood and Gastric Cancer Risk: A Nested Caseâ€"Control Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 470-476.	1.1	6
327	MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis . OncoTargets and Therapy, 2020, Volume 13, 2491-2510.	1.0	65
328	Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. Oral Oncology, 2021, 112, 105074.	0.8	12
329	Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells. Phytomedicine, 2021, 80, 153355.	2.3	16
330	Hepatocyte growth factor prevents pericyte loss in diabetic retinopathy. Microvascular Research, 2021, 133, 104103.	1.1	9
331	Recent developments in antibody derivatives against colorectal cancer; A review. Life Sciences, 2021, 265, 118791.	2.0	18
332	A Phase II Study of Telisotuzumab Vedotin in Patients With câ€"MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer, 2021, 22, 170-177.	1.1	41
333	Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. International Journal of Biological Macromolecules, 2021, 167, 1030-1047.	3.6	34
334	HGF/c-Met Signalling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 31-44.	0.8	20
335	Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses. Nature Biotechnology, 2021, 39, 215-224.	9.4	21
336	Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels. Investigational New Drugs, 2021, 39, 77-88.	1.2	12
337	Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women. Cancer Research, 2021, 81, 3008-3021.	0.4	11
338	A Randomized, Doubleâ€Blind, Placeboâ€•and Positiveâ€Controlled, Threeâ€Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval. Clinical Pharmacology in Drug Development, 2021, 10, 521-534.	0.8	6
339	Human Telomerase Reverse Transcriptase Promotes the Epithelial to Mesenchymal Transition in Lung Cancer Cells by Enhancing c-MET Upregulation. SSRN Electronic Journal, 0, , .	0.4	0
340	Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. Journal of Cancer, 2021, 12, 644-651.	1.2	8
341	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling. EBioMedicine, 2021, 63, 103191.	2.7	9
342	MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma. Brazilian Journal of Medical and Biological Research, 2021, 54, e10877.	0.7	2
343	MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinomaâ€"Current Understanding and Therapeutic Advances. Oncology & Hematology Review, 2021, 16, 100.	0.2	2

#	Article	IF	Citations
344	Antibodyâ€“drug conjugates in solid tumors: a look into novel targets. Journal of Hematology and Oncology, 2021, 14, 20.	6.9	129
345	Expression and Clinical Significance of <i>PIK3CA</i>, <i>c-MET</i> and <i>c-KIT</i> Mutations in Saudi Breast Cancer Patients. Advances in Breast Cancer Research, 2021, 10, 60-74.	0.1	0
346	Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines, 2021, 9, 39.	1.4	18
347	The role of MET in chemotherapy resistance. Oncogene, 2021, 40, 1927-1941.	2.6	54
348	Antiâ€tumor efficacy of human antiâ€câ€met CARâ€T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Science, 2021, 112, 1417-1428.	1.7	21
349	Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway. Oncology Letters, 2021, 21, 326.	0.8	4
350	The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. Journal of Experimental and Clinical Cancer Research, 2021, 40, 69.	3.5	12
351	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. Biology, 2021, 10, 146.	1.3	13
352	New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 327-342.	0.9	5
353	miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. Life Sciences, 2021, 268, 118925.	2.0	29
354	Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling. Cancers, 2021, 13, 1432.	1.7	6
355	Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 2021, 13, 1115.	1.7	36
356	Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition. Cancer Chemotherapy and Pharmacology, 2021, 87, 827-842.	1.1	13
357	MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opinion on Therapeutic Targets, 2021, 25, 249-268.	1.5	22
358	Molecular Processes Involved in Pancreatic Cancer and Therapeutics. Current Chemical Biology, 2021, 15, 85-108.	0.2	0
359	Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma. Anticancer Research, 2021, 41, 1811-1819.	0.5	6
360	RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers, 2021, 13, 1685.	1.7	26
361	Understanding stem cells and its pivotal role in regenerative medicine. Life Sciences, 2021, 273, 119270.	2.0	12

#	Article	IF	Citations
362	Targeting the VEGF Pathway in Osteosarcoma. Cells, 2021, 10, 1240.	1.8	24
363	The utility of câ€Met as a diagnostic tissue biomarker in primary colorectal cancer. International Journal of Experimental Pathology, 2021, 102, 172-178.	0.6	8
364	Loss of Apc Cooperates with Activated Oncogenes to Induce Liver Tumor Formation in Mice. American Journal of Pathology, 2021, 191, 930-946.	1.9	4
365	High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Scientific Reports, 2021, 11, 11376.	1.6	6
366	Opposed Interplay between IDH1 Mutations and the WNT/Î²-Catenin Pathway: Added Information for Glioma Classification. Biomedicines, 2021, 9, 619.	1.4	5
367	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 201.	7.1	607
368	Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma. Scientific Reports, 2021, 11, 12466.	1.6	5
369	Neurotrophic Factors Secreted by Induced Pluripotent Stem Cell-Derived Retinal Progenitors Promote Retinal Survival and Preservation in an Adult Porcine Neuroretina Model. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 301-312.	0.6	3
370	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
371	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs, 2021, 39, 1577-1586.	1.2	3
372	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3453.	1.7	6
373	Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 1008-1046.	2.9	28
374	Novel fusion genes in spindle cell rhabdomyosarcoma: The spectrum broadens. Genes Chromosomes and Cancer, 2021, 60, 687-694.	1.5	17
375	Structural basis of the activation of c-MET receptor. Nature Communications, 2021, 12, 4074.	5.8	64
376	Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione Derivatives. Frontiers in Pharmacology, 2021, 12, 691234.	1.6	17
377	Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Cancer Letters, 2021, 512, 51-59.	3.2	13
378	Treatment of Lung Cancer Targeting <i>MET</i> Alterations. Japanese Journal of Lung Cancer, 2021, 61, 273-281.	0.0	0
379	Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers. Cancers, 2021, 13, 4137.	1.7	22

#	Article	IF	Citations
380	Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in nonâ€"small cell lung cancer patients in resource constrained community hospitals. Journal of Pathology and Translational Medicine, 2021, 55, 324-329.	0.4	1
382	Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers. Current Oncology, 2021, 28, 3717-3728.	0.9	8
383	Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype. Molecular Cancer Research, 2021, 19, 2026-2035.	1.5	6
384	Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nature Communications, 2021, 12, 5389.	5.8	14
385	Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 2021, 38, 54-61.	1.0	10
386	New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. Bioorganic and Medicinal Chemistry, 2021, 46, 116340.	1.4	5
387	Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 9685.	1.8	11
388	Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Molecular Therapy - Oncolytics, 2021, 22, 166-179.	2.0	17
389	Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 1475-1475.	0.7	3
390	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. Cells, 2021, 10, 2382.	1.8	29
391	Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. American Journal of Pathology, 2021, 191, 2052-2063.	1.9	22
392	Knockout of Hepatocyte Growth Factor by CRISPR/Cas9 System Induces Apoptosis in Hepatocellular Carcinoma Cells. Journal of Personalized Medicine, 2021, 11, 983.	1.1	7
393	STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells. Cancer Letters, 2021, 519, 328-342.	3.2	10
395	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respiratory Medicine,the, 2021, 9, 1154-1164.	5.2	107
396	Potential underlying genetic associations between keratoconus and diabetes mellitus. Advances in Ophthalmology Practice and Research, 2021, 1, 100005.	0.3	8
397	Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives. Bioorganic Chemistry, 2021, 116, 105304.	2.0	7
398	Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature. Biomedicine and Pharmacotherapy, 2021, 143, 112190.	2.5	24
399	Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras). , 2022, , 889-904.		0

#	Article	IF	Citations
400	Narrative review: mesenchymal-epithelial transition inhibitorsâ€"meeting their target. Translational Lung Cancer Research, 2021, 10, 462-474.	1.3	6
401	Molecular profiling of soft-tissue sarcomas with FoundationOne^{Â®} Heme identifies potential targets for sarcoma therapy: a single-centre experience. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110291.	1.4	3
402	Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. Frontiers in Oral Health, 2020, 1, 603160.	1.2	32
403	Lung Cancer Receptors and Targeting Strategies. AAPS Advances in the Pharmaceutical Sciences Series, 2019, , 229-268.	0.2	2
404	The HGF/MET Signaling and Therapeutics in Cancer. Current Human Cell Research and Applications, 2018, , 155-181.	0.1	5
405	Progress on treatment of MET signaling pathway in non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 1450-1458.	1.0	4
406	Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorganic Chemistry, 2020, 101, 103970.	2.0	14
407	The beginning of the end for conventional RECIST â€" novel therapies require novel imaging approaches. Nature Reviews Clinical Oncology, 2019, 16, 442-458.	12.5	97
408	Glycosylated Peptide Materials. RSC Soft Matter, 2020, , 335-362.	0.2	3
411	MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e84319.	1.1	17
412	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. PLoS ONE, 2015, 10, e0128360.	1.1	23
413	Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells. PLoS ONE, 2016, 11, e0148075.	1.1	4
414	Role of Growth Factor Signaling in Cancer. Defence Life Science Journal, 2016, 1, 34.	0.1	3
415	c-Met as a new marker of cellular senescence. Aging, 2019, 11, 2889-2897.	1.4	11
416	Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. Genes and Cancer, 2017, 8, 628-639.	0.6	33
417	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget, 2016, 7, 57651-57670.	0.8	29
418	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget, 2017, 8, 35193-35204.	0.8	10
419	Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget, 2018, 9, 13682-13693.	0.8	39

#	Article	IF	Citations
420	Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines. Oncotarget, 2018, 9, 18254-18268.	0.8	21
421	Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway. Oncotarget, 2018, 9, 35907-35921.	0.8	27
422	c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations. Oncotarget, 2015, 6, 31640-31658.	0.8	18
423	TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget, 2016, 7, 23715-23729.	0.8	17
424	Biomarker development in MET-targeted therapy. Oncotarget, 2016, 7, 37370-37389.	0.8	38
425	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget, 2016, 7, 27379-27393.	0.8	8
426	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Annals of Translational Medicine, 2017, 5, 2-2.	0.7	42
427	Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. Anticancer Research, 2017, 37, 3871-3876.	0.5	10
428	Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor. Radiation Oncology Journal, 2015, 33, 328.	0.7	10
429	MicroRNAâ€‘206 exerts antiâ€‘oncogenic functions in esophageal squamous cell carcinoma by suppressing the câ€‘Met/AKT/mTOR pathway. Molecular Medicine Reports, 2019, 19, 1491-1500.	1.1	9
430	Curcumin inhibits epithelialâ€‘mesenchymal transition in oral cancer cells via câ€‘Met blockade. Oncology Letters, 2020, 19, 4177-4182.	0.8	19
431	Biology of MET: a double life between normal tissue repair and tumor progression. Annals of Translational Medicine, 2015, 3, 82.	0.7	38
432	Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 215.	0.8	26
433	Expression of c-MET in Invasive Meningioma. Journal of Pathology and Translational Medicine, 2015, 49, 44-51.	0.4	24
434	A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. Molecular Imaging and Radionuclide Therapy, 2017, 26, 102-117.	0.3	8
435	The role of microRNA in metastatic processes of non-small cell lung carcinoma. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 343-357.	0.2	28
436	Novel C1q receptor-mediated signaling controls neural stem cell behavior and neurorepair. ELife, 2020, 9, .	2.8	18
437	The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma. , 2021, 4, 923-933.		1

#	Article	IF	Citations
438	Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies. Medical Oncology, 2021, 38, 143.	1.2	3
439	MET Amplification in Non-Small Cell Lung Cancer (NSCLC)â€"A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. Cancers, 2021, 13, 5023.	1.7	21
440	Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer. , 2015, , 157-185.		0
441	Sebaceous carcinoma of skin expressing KIT and PDGFRA. Case Reports in Clinical Pathology, 2016, 3, .	0.0	0
442	Proteins Flexibility as a Criterion for Elucidation of Activating Mutants in Personalized Cancer Medicine. Advances in Intelligent Systems and Computing, 2018, , 75-82.	0.5	0
443	Current and Emerging Medical Therapies for Advanced Disease in Intrahepatic Cholangiocarcinoma. , 2018, , 137-151.		0
444	c-MET in Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 63-88.	0.2	1
445	Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer â€" The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study. European Oncology and Haematology, 2019, 15, 86.	0.0	0
446	Apoptotic Effects of Mucin1 Aptamer-Conjugated Nanoparticles Containing Docetaxel and c-Met siRNA on SKBR3 Human Metastatic Breast Cancer Cells. Jundishapur Journal of Natural Pharmaceutical Products, 2019, 14, .	0.3	1
448	Hepatocyte Growth Factor and Macrophage-stimulating Protein â€œHingeâ€•Analogs to Treat Pancreatic Cancer. Current Cancer Drug Targets, 2019, 19, 782-795.	0.8	1
449	Molecular Biology of Iris. , 2020, , 105-160.		0
450	Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020, 164, 127-132.	0.2	1
451	Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 412-427.	0.9	4
452	The Canonical Wnt Signaling (Wnt/Î²-Catenin Pathway): A Potential Target for Cancer Prevention and Therapy. Iranian Biomedical Journal, 2020, 24, 264-275.	0.4	12
453	MicroRNAâ€'206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the câ€'Met/AKT/GSKâ€'3Î² pathway. Oncology Letters, 2020, 21, 147.	0.8	9
454	Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells. Oncology Research, 2020, 28, 497-507.	0.6	3
455	Ancillary Studies Applied to Renal Masses. , 2020, , 209-243.		0
456	Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 559-570.	0.9	1

#	Article	IF	Citations
457	Molecular mechanisms of lymphatic metastasis in solid tumors of the gastrointestinal tract. International Journal of Clinical and Experimental Pathology, 2012, 5, 614-23.	0.5	17
459	Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis. , 2019, 2, 1-13.		3
461	The biogenesis and roles of extrachromosomal oncogene involved in carcinogenesis and evolution. American Journal of Cancer Research, 2020, 10, 3532-3550.	1.4	4
462	suppresses cell growth via MET/STAT3 signaling in lung cancer. American Journal of Translational Research (discontinued), 2021, 13, 1221-1232.	0.0	2
463	Recent advances in lung cancer genomics: Application in targeted therapy. Advances in Genetics, 2021, 108, 201-275.	0.8	5
464	A novel fluorescent c-met targeted imaging agent for intra-operative colonic tumour mapping: Translation from the laboratory into a clinical trial. Surgical Oncology, 2022, 40, 101679.	0.8	3
465	Kinase Inhibitorsâ€™ Effects on Innate Immunity in Solid Cancers. Cancers, 2021, 13, 5695.	1.7	5
466	Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics. OncoTargets and Therapy, 2021, Volume 14, 5321-5331.	1.0	4
467	Targeting Oncogene Addiction for Cancer Therapy. , 0, , .		0
468	An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert Opinion on Therapeutic Patents, 2022, 32, 279-298.	2.4	7
469	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology, 2021, 28, 4552-4576.	0.9	4
470	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 â€œCREATEâ€•Trial. Cancers, 2021, 13, 6057.	1.7	9
471	Bone marrow mesenchymal stem cells overexpressing hepatocyte growth factor ameliorate hypoxicâ€“ischemic brain damage in neonatal rats. Translational Neuroscience, 2021, 12, 561-572.	0.7	2
472	Human telomerase reverse transcriptase promotes the epithelial to mesenchymal transition in lung cancer cells by enhancing c-MET upregulation. Heliyon, 2022, 8, e08673.	1.4	3
473	Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer. ESMO Open, 2022, 7, 100347.	2.0	4
474	Synthesis of 2,7-diarylpyrazolo [1,5-a] pyrimidine derivatives with antitumor activity. Theoretical identification of targets. European Journal of Medicinal Chemistry Reports, 2022, 4, 100028.	0.6	5
475	Immunohistochemical Expression of â€œc-METâ€•in Breast Carcinomas. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 824-832.	0.1	0
476	Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article). Clinical and Experimental Medicine, 2023, 23, 203-218.	1.9	4

#	Article	IF	Citations
477	c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells <i>in vitro</i> and <i>in vivo</i>. Journal of Biomedical Research, 2022, 36, 10.	0.7	9
478	Pulmonary Mesenchymal Stem Cells in Mild Cases of COVID-19 Are Dedicated to Proliferation; In Severe Cases, They Control Inflammation, Make Cell Dispersion, and Tissue Regeneration. Frontiers in Immunology, 2021, 12, 780900.	2.2	8
479	KRAS and MET in non-small-cell lung cancer: two of the new kids on the â€˜driversâ€™ block. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662110660.	1.0	6
480	Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers. Oncologist, 2022, 27, 342-e383.	1.9	8
481	MicroRNAs: Emerging Regulators of Metastatic Bone Disease in Breast Cancer. Cancers, 2022, 14, 729.	1.7	12
482	Fused pyrrolo-pyridines and pyrrolo-(iso)quinoline as anticancer agents. ChemistrySelect, 2023, 8, 2583-2645.	0.7	2
483	Imaging of the Peptide Functionalized Met-Targeting Probe Using T1 Mapping in Detecting Marginal Infiltration of GBM. SSRN Electronic Journal, 0, , .	0.4	0
484	Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology, 2022, 105, 108585.	1.7	2
485	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. Annals of Diagnostic Pathology, 2022, 58, 151909.	0.6	1
486	Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. Journal of Medicinal Chemistry, 2021, 64, 18158-18174.	2.9	8
487	Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach. Cancer Drug Resistance (Alhambra, Calif), 0, , .	0.9	4
488	NPS-1034 Induce Cell Death with Suppression of TNFR1/NF-ÎºB Signaling in Testicular Cancer. Medicina (Lithuania), 2022, 58, 355.	0.8	0
489	Human Growth Factor/Immunoglobulin Complexes for Treatment of Myocardial Ischemia-Reperfusion Injury. Frontiers in Bioengineering and Biotechnology, 2022, 10, 749787.	2.0	1
490	Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling. Seminars in Cancer Biology, 2022, 86, 1086-1104.	4.3	25
491	Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology, 2022, 13, 838133.	1.6	39
492	Recent progress in the imaging of câ€Met aberrant cancers with positron emission tomography. Medicinal Research Reviews, 2022, 42, 1588-1606.	5.0	12
493	A Quality Control Mechanism of Splice Site Selection Abrogated under Stress and in Cancer. Cancers, 2022, 14, 1750.	1.7	2
494	Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype. Molecular Carcinogenesis, 2022, 61, 537-548.	1.3	2

#	Article	IF	Citations
495	A concise review on tyrosine kinase targeted cancer therapy. Current Drug Therapy, 2022, 17, .	0.2	1
496	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimerâ€™s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. Journal of Alzheimer's Disease, 2022, 86, 1399-1413.	1.2	15
497	Met inhibitors in the treatment of lung cancer: the evidence to date. Expert Opinion on Pharmacotherapy, 2022, , .	0.9	0
498	Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors. Frontiers in Chemistry, 2022, 10, 815534.	1.8	4
499	Appraisal of hepatocyte growth factor signal transduction in the duality of HIV associated pre-eclampsia. Pregnancy Hypertension, 2022, 28, 128-133.	0.6	1
502	Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation. Computers in Biology and Medicine, 2022, 146, 105526.	3.9	6
508	RNAâ€Seq reveals the functional specificity of epididymal caput, corpus, and cauda genes of cattleyak. Animal Science Journal, 2022, 93, e13732.	0.6	5
509	ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer. Cell Death and Disease, 2022, 13, 417.	2.7	12
510	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers, 2022, 14, 2393.	1.7	8
511	Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response. PLoS ONE, 2022, 17, e0268217.	1.1	3
512	Metformin-induced downregulation of c-Met is a determinant of sensitivity in MDA-MB-468 breast cancer cells. Biochemical and Biophysical Research Communications, 2022, 613, 100-106.	1.0	2
513	Presumed bilateral diffuse uveal melanocytic proliferation â€“ A case report and review of literature. American Journal of Ophthalmology Case Reports, 2022, 27, 101582.	0.4	3
514	Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer: Targets and Therapy, 2022, Volume 13, 33-45.	1.3	6
515	Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1667-1677.	1.2	11
516	Artonin F Induces the Ubiquitin-Proteasomal Degradation of c-Met and Decreases Akt-mTOR Signaling. Pharmaceuticals, 2022, 15, 633.	1.7	4
517	Targeting Glioma Cells with Nutraceuticals: Therapeutic Effects Based on Molecular Mechanisms, New Evidence and Perspectives. Mini-Reviews in Medicinal Chemistry, 2023, 23, 1167-1192.	1.1	2
518	Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review. Chemico-Biological Interactions, 2022, 363, 110000.	1.7	3
519	An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 472-486.	0.9	12

#	Article	IF	Citations
520	Cryo-electron Microscopic Analysis of Single-Pass Transmembrane Receptors. Chemical Reviews, 2022, 122, 13952-13988.	23.0	7
521	Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophe as a potential anti-colorectal cancer agent. European Journal of Medicinal Chemistry, 2022, 239, 114561.	6.0	
522	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
523	InlB protein secreted by Listeria monocytogenes controls the pathogen interaction with macrophages. Bulletin of Russian State Medical University, 2022, , .	0.3	0
524	Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease. Drugs in Context, 0, 11, 1-10.	1.0	1
525	Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Clinical Oncology, 2022, 34, e451-e462.	0.6	6
526	Case Report: Gene Heterogeneity in the Recurrent and Metastatic Lesions of a Myxoid Chondrosarcoma Patient With Aggressive Transformation. Frontiers in Genetics, 0, 13, .	1.1	0
527	Long non-coding RNA NR2F2-AS1: its expanding oncogenic roles in tumor progression. Human Cell, 2022, 35, 1355-1363.	1.2	4
528	Core cysteine residues in the Plasminogen-Apple-Nematode (PAN) domain are critical for HGF/c-MET signaling. Communications Biology, 2022, 5, .	2.0	5
529	MET: A narrative review of exon 14 skipping mutation in non-small-cell lung carcinoma. Cancer Research Statistics and Treatment, 2022, 5, 284.	0.1	4
530	Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery. Cells, 2022, 11, 2322.	1.8	8
531	Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. Journal of Cachexia, Sarcopenia and Muscle, 0, , .	2.9	4
532	Sotorasib and other drugs comparison in treating non-small cell lung cancer. , 0, 8, 675-686.		0
533	c-Met: A Promising Therapeutic Target in Bladder Cancer. Cancer Management and Research, 0, Volume 14, 2379-2388.	0.9	8
534	Effect of ovulation IGF and HGF signaling on the oncogenesis of murine epithelial ovarian cancer cell ID8. Experimental Cell Research, 2022, 419, 113323.	1.2	1
535	Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer. Biomolecules, 2022, 12, 1197.	1.8	0
536	The Growth Factors: Potential Biomarkers and Therapeutic Targets in Kidney Diseases. Kidney Diseases (Basel, Switzerland), 0, , 1-13.	1.2	0
537	Fibroblast-derived Hgf controls recruitment and expansion of muscle during morphogenesis of the mammalian diaphragm. ELife, 0, 11, .	2.8	6

#	Article	IF	Citations
538	Aptamer-Functionalized Nanodevices for Dynamic Manipulation of Membrane Receptor Signaling in Living Cells. Nano Letters, 2022, 22, 7853-7859.	4.5	12
539	Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations. JTO Clinical and Research Reports, 2022, 3, 100407.	0.6	2
540	Constructing biomimetic liver models through biomaterials and vasculature engineering. Regenerative Biomaterials, 2022, 9, .	2.4	9
541	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , .		0
542	Covalent stabilization of DNA nanostructures on cell membranes for efficient surface receptor-mediated labeling and function regulations. Science China Chemistry, 2022, 65, 2327-2334.	4.2	1
543	Aptamer Inhibits Tumor Growth by Leveraging Cellular Proteasomal Degradation System to Degrade câ€Met in Mice. Angewandte Chemie, 0, , .	1.6	0
544	Aptamer Inhibits Tumor Growth by Leveraging Cellular Proteasomal Degradation System to Degrade câ€Met in Mice. Angewandte Chemie - International Edition, 2023, 62, .	7.2	4
545	B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. IScience, 2022, 25, 105419.	1.9	3
546	Semaphorin 4D induces articular cartilage destruction and inflammation in joints by transcriptionally reprogramming chondrocytes. Science Signaling, 2022, 15, .	1.6	4
547	CD44v6+ Hepatocellular Carcinoma Cells Maintain Stemness Properties through Met/cJun/Nanog Signaling. Stem Cells International, 2022, 2022, 1-16.	1.2	2
548	Impairment of peripheral nerve regeneration by insufficient activation of the HGF/c-Met/c-Jun pathway in aged mice. Heliyon, 2022, 8, e11411.	1.4	3
549	Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. Frontiers in Chemistry, 0, 10, .	1.8	2
550	Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma. BMC Medical Genomics, 2022, 15, .	0.7	2
551	Thymoquinone-treated mouse mesenchymal stem cells-derived conditioned medium inhibits human breast cancer cells in vitro. Chemico-Biological Interactions, 2023, 369, 110283.	1.7	4
552	MET Inhibition in Non-Small Cell Lung Cancer. European Medical Journal (Chelmsford, England), 0, , 100-111.	3.0	3
553	Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug-Resistant Human Uterine Sarcoma Cells. International Journal of Molecular Sciences, 2022, 23, 14884.	1.8	2
554	Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine (United States), 2022, 101, e32368.	0.4	0
555	Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase. Pharmaceutics, 2022, 14, 2829.	2.0	6

#	Article	IF	Citations
556	Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics, 2023, 20, 431-451.	2.1	9
557	The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer. Current Pharmaceutical Design, 2022, 28, 3563-3571.	0.9	2
558	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine, 2022, 3, .	1.7	8
559	The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome. Pediatric Surgery International, 2023, 39, .	0.6	2
560	EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. ELife, 0, 12, .	2.8	4
561	Harnessing Peptide-Functionalized Multivalent Gold Nanorods for Promoting Enhanced Gene Silencing and Managing Breast Cancer Metastasis. ACS Applied Bio Materials, 0, , .	2.3	5
562	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. Veterinary Sciences, 2023, 10, 19.	0.6	4
563	Met/HGFR triggers detrimental reactive microglia in TBI. Cell Reports, 2022, 41, 111867.	2.9	7
564	Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe, 2022, 18, 220147.	0.6	4
565	Hypoxia-inducible factor 1Î± inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells. BMB Reports, 2023, 56, 78-83.	1.1	1
566	Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. , 2023, , 201-235.		1
567	The Behaviour of Cancers: Invasion and Metastasis II. Experimental Analysis of Mechanisms. , 2023, , 175-227.		0
568	Standard aberration: cancer biology and the modeling account of normal function. Biology and Philosophy, 2023, 38, .	0.7	1
569	Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to <i>Mesenchymal-epithelial Transition</i> Amplification in a Lung Cancer Patient with the <i>Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase</i> Fusion Gene. Internal Medicine, 2023, , .	0.3	2
570	Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188869.	3.3	1
571	Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. Neoplasia, 2023, 39, 100894.	2.3	3
572	Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review. Journal of Oncology Pharmacy Practice, 2023, 29, 1187-1195.	0.5	1
573	Finding Normality in Abnormality: On the Ascription of Normal Functions to Cancer. Philosophy of Science, 2023, 90, 1214-1223.	0.5	0

#	Article	IF	Citations
574	Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist, 2023, 28, 425-432.	1.9	1
575	Recent progress in targeted therapy for non-small cell lung cancer. Frontiers in Pharmacology, 0, 14, .	1.6	11
576	Radiogenomics in Renal Cancer Managementâ€"Current Evidence and Future Prospects. International Journal of Molecular Sciences, 2023, 24, 4615.	1.8	33
577	The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. Cancers, 2023, 15, 1597.	1.7	6
578	Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutationâ€"Positive, MET-Amplified Nonâ€"Small Cell Lung Cancer Model. Molecular Cancer Therapeutics, 2023, 22, 679-690.	1.9	0
579	Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma. Veterinary Sciences, 2023, 10, 249.	0.6	0
580	MACC1-induced migration in tumors: Current state and perspective. Frontiers in Oncology, 0, 13, .	1.3	1
581	A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311563.	1.4	3
582	Landscape of NcRNAs involved in drug resistance of breast cancer. Clinical and Translational Oncology, 2023, 25, 1869-1892.	1.2	4
587	Approved and investigational fluorescent optical imaging agents for disease detection in surgery. International Journal of Surgery, 2023, 109, 2378-2387.	1.1	1
614	Histology and molecular testing. , 2024, , 69-100.		0
615	Molecular testing in lung cancer. , 2024, , 319-337.		0
618	3D tumor spheroids: morphological alterations a yardstick to anti-cancer drug response. In Vitro Models, 2023, 2, 219-248.	1.0	1
619	Other molecular cohorts including ROS1, BRAF, HER2, MET, NTRK, RET, KRAS. , 2024, , 269-282.		0